Interventional Oncology Features
Green Paper
08/14/2026
Laura Simson, MA
The EU Joint Action Networks of Expertise on Cancer (JANE-2) green paper examines emerging applications and strategies for integrating physical tumor ablation methods into oncology care.
The EU Joint Action Networks of Expertise on Cancer (JANE-2) green paper examines emerging applications and strategies for integrating physical tumor ablation methods into oncology care.
The EU Joint Action Networks of...
08/14/2026
Vascular Disease Management
Phase 3 Randomized Clinical Trial
08/11/2026
Laura Simson, MA
Adding selective radiofrequency ablation after transarterial chemoembolization significantly improved survival outcomes among patients with liver-confined, unresectable hepatocellular carcinoma, according to the phase 3 TORCH randomized...
Adding selective radiofrequency ablation after transarterial chemoembolization significantly improved survival outcomes among patients with liver-confined, unresectable hepatocellular carcinoma, according to the phase 3 TORCH randomized...
Adding selective radiofrequency...
08/11/2026
Vascular Disease Management
ASCO 2026
07/13/2026
Ghassan Abou-Alfa, MD, MBA
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses...
07/13/2026
Vascular Disease Management
Interview
06/15/2026
Michael Pishvaian, MD, PhD
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD,...
06/15/2026
Vascular Disease Management
Interview
03/13/2026
Dania Daye, MD, PhD
Dr Dania Daye discusses the need for standardized reporting in AI studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need for standardized reporting in AI studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need...
03/13/2026
Vascular Disease Management
Video
03/13/2026
Dania Daye, MD, PhD
Dr Dania Daye discusses the need for standardized reporting in artificial intelligence (AI) studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need for standardized reporting in artificial intelligence (AI) studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need...
03/13/2026
Vascular Disease Management
Interview
11/25/2025
Kyle S. Stumetz, DO
Kyle S. Stumetz, DO, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, DO, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, DO, winner of...
11/25/2025
Vascular Disease Management
CIO 2025
11/25/2025
Kyle S. Stumetz, DO; Laura Simson, MA
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the...
11/25/2025
Vascular Disease Management
Case Study
09/26/2025
Edgar St. Amour, MD; Nadine Abi-Jaoudeh, MD
These cases were part of the Instylla HES Hypervascular Tumor Pivotal Study to evaluate the safety and effectiveness of Embrace HES compared with standard of care TAE or TACE.
These cases were part of the Instylla HES Hypervascular Tumor Pivotal Study to evaluate the safety and effectiveness of Embrace HES compared with standard of care TAE or TACE.
These cases were part of the...
09/26/2025
Vascular Disease Management
Sponsored Video
09/26/2025
J. David Prologo, MD, FSIR
Join Dr Prologo for a groundbreaking look at a dual-level kyphoplasty procedure using the OsteoCool 2.0 system. This exclusive video captures real-time ablation and cement injection at two vertebral levels with 10-gauge cannulas, complete...
Join Dr Prologo for a groundbreaking look at a dual-level kyphoplasty procedure using the OsteoCool 2.0 system. This exclusive video captures real-time ablation and cement injection at two vertebral levels with 10-gauge cannulas, complete...
Join Dr Prologo for a...
09/26/2025
Vascular Disease Management
